Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab

समान संसाधन

• Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
  द्वारा: Tanaka, Yoshiya, और अन्य
  प्रकाशित: (2015)
• Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)
  द्वारा: Kaneko, Yuko, और अन्य
  प्रकाशित: (2018)
• Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study
  द्वारा: Hirata, Shintaro, और अन्य
  प्रकाशित: (2013)
• 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage
  द्वारा: Maksymowych, Walter P, और अन्य
  प्रकाशित: (2014)
• Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages
  द्वारा: Trimova, Gulzhan, और अन्य
  प्रकाशित: (2020)